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Management Programs for Diabetes in 2003 leading to intensification of antihyper-
glycemic therapy and thus increasing the risk for SH.
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HYPOGLYCAEMIA-RELATED HOSPITALIZATIONS AMONG NEWS USERS OF
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OBJECTIVES: Hypoglycaemia is a major side effect of antidiabetes drugs. Mild ep-
isodes of hypoglycaemia are frequent and are generally self-treated. On the other
hand, severe hypoglycaemia can have deleterious effects on mortality, morbidity
and quality of life. The objective was to describe the burden of severe hypoglycae-
mia among new users of insulin and oral antidiabetes drugs (OAD) in terms of two
hypoglycaemia-related outcomes: emergency department (ED) visit and hospital-
ization. More specifically: 1) to describe the frequency of hypoglycaemia-related ED
visits and hospitalizations, and 2) to calculate the incidence rate of these two
outcomes. METHODS: We conducted an inception cohort study using the data-
bases of the Quebec health insurance board and the Quebec registry of hospital-
izations. The source population was made of individuals aged 18 years or over;
newly dispensed an antidiabetes treatment made of either insulin or OAD between
January 1, 2000 and December 31, 2008. Individuals were followed from initiation of
antidiabetes treatment to December 31, 2008, occurrence of hypoglycaemia-related
outcome, loss of eligibility to the drug plan or death, whichever came first. Individ-
uals’ characteristics at antidiabetes treatment initiation were described using fre-
quency distributions. The incidence rate for the occurrence of hypoglycaemia-
related ED visit and hypoglycaemia-related hospitalization were calculated using
the Kaplan–Meier method. RESULTS: A total of 188,659 new users of antidiabetes
treatment were included in the cohort. A total of 3575 (1.9%) individuals had at least
one hypoglycaemia-related ED visit while 194 (0.1%) had at least one hypoglycae-
mia-related hospitalization. Incidence rates for the occurrence of hypoglycaemia-
related ED visits and hypoglycaemia-related hospitalizations were 5.2, and 0.3
cases per 1000 patient-years, respectively. CONCLUSIONS: Although the incidence
of ED visit or hospitalization due to hypoglycaemia seems low, severe hypoglycae-
mia episodes could be associated with a high economic burden.
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OBJECTIVES: To assess whether the presence of type 2 diabetes mellitus (T2DM)
increases the risk of urinary tract infections (UTI) in men and women. METHODS:
In a retrospective cohort study, patients 18 years with a diagnosis of T2DM or
prescriptions for antihyperglycaemic therapy were identified within MarketScan, a
US-based insurance claims database. Date of first T2DM diagnosis or prescription
in 2008 was the index date. Patients without T2DM were age and gender matched to
those with T2DM. Eligible patients had medical records for 1 year prior to (baseline)
and 1 year after (follow up) the index date. UTI diagnosis during follow up was
assessed with ICD-9 codes. Logistic regression adjusted for patient characteristics
and comorbid conditions was used to assess the likelihood of experiencing UTI.
RESULTS: A total of 106,623 matched pairs were selected. The mean age at index
date was 56 years and 50% were male. Patients with T2DM had more pre-existing
comorbid conditions compared to patients without T2DM. In the 1-year follow up,
more patients with T2DM were diagnosed with UTI (12.9% vs. 7.7%; p0.0001)
compared to non-T2DM patients. The proportion of women with T2DM experienc-
ing UTI was greater (18.3% vs. 11.8%; p0.0001) than for women without T2DM. A
lower proportion of men had UTI, but the difference between T2DM and no T2DM
remained and was significant (7.6% vs. 3.6%; p0.0001). In a logistic regression,
patients with T2DM had a greater likelihood of experiencing UTI during follow up
(adjusted odds ratio 1.71 [95% CI 1.66, 1.77]). For each gender alone, the odds were
still significantly greater for patients with T2DM. Measurements of glycemic con-
trol were not available and thus their influence on UTI risk could not be assessed.
CONCLUSIONS: Patients with T2DM were more likely to experience a UTI com-
pared to patients without T2DM.
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OBJECTIVES:Analog insulin glulisine has a higher efficacy in reducing postprandial
glucose excursions and in restoring normal postprandial microcirculation than
regular human insulins. Besides glycemic control, insulin glulisine has also favor-
able effects in maintaining normal endothelial function. Therefore, the aim was to
compare the incidence of macro- and microvascular outcomes in type 2 diabetic
patients treated with insulin glulisine or regular human insulin. METHODS: Com-
puterized data from 952 glulisine (age: 61 11 yrs) and 11,157 regular insulin (65
11 yrs) users in general practices throughout Germany (Disease Analyzer, 11/2004
to 3/2010) were analysed. Hazard ratios (HR; Cox regression) for 3.5-year risk of
macro- or microvascular outcomes were adjusted for age, sex, diabetes duration,
health insurance, residency, diabetologist care, hypertension, hyperlipidemia, de-
pression, and co-medication (basal insulin, oral antidiabetics). Furthermore, ad-
justment was carried out for baseline microvascular complications when analyz-
ing macrovascular outcomes and vice versa.RESULTS:Overall, risk for both macro-
and microvascular outcomes was 20% lower for patients using insulin glulisine
(p0.05). There was a decreased risk for coronary heart disease (HR; 95% CI: 0.78;
0.62–0.99), and a trend for lower events of myocardial infarction (0.66; 0.43–1.02).
Also for microvascular complications, the adjusted hazard ratios for retinopathy,
nephropathy and neuropathy were below 1.0, indicating a lower risk for the insulin
glulisine group, however, which was statistically significant for neuropathy only
(0.74; 0.58–0.93). CONCLUSIONS: The prescription of the rapid-acting insulin ana-
log glulisine was associated with a reduced incidence of macro- and microvascular
outcomes in type 2 diabetes under real-life conditions in a retrospective database
analysis. It is important to confirm this finding in a randomized controlled trial.
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OBJECTIVES: The World Health Organization has recognized diabetes and other
selected chronic health conditions are at an epidemic level all of which can be
impacted by weight. The purpose of this project was to classify US adults by Body
Mass Index (BMI) categories and compare adults with diabetes to those adults
without diabetes by BMI categories and other selected priority health conditions to
see if there was a difference between groups. METHODS: The Medical Expenditure
Panel Survey (MEPS) is publically available database providing nationally represen-
tative estimates of health care use, expenditures, sources of payment, and health
insurance coverage for the US population. Analysis of the survey data utilized
design-based methods that utilized the complex survey stratification and weight-
ing provided within the MEPS datasets, in addition to use of the Rao-Scott Chi-
square test, to compare people with and without diabetes. The level of significance
was two-tailed 0.05. RESULTS: In 2008, approximately 64 percent of the U.S.
adult population was overweight (BMI of 25.0 to 29.9), obese (BMI of 30.0 to 39.9), or
extremely obese (BMI greater than or equal to 40). Adults with diabetes had signif-
icantly higher percentages of being overweight, obese, and extremely obese, where
more likely to have asthma and more than twice as likely to have hypertension,
and were nearly three times as likely to have heart disease and more than three
times more likely to have a stroke than adults without diabetes (p-value0.001).
CONCLUSIONS: Patients with diabetes were more likely to be overweight, obese,
and extremely obese compared to those without diabetes. Patients with diabetes
were also more likely to have chronic health conditions such as hypertension,
heart disease, and stroke.
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OBJECTIVES: To determine the prevalence and incidence of Lantus vs NPH and
premix insulin use in diabetes including the treatment characteristics, comorbidity
and resource use in a representative population in Canada. METHODS: Records
from a longitudinal population-based database of more than 225,000 primary care
patients in southwestern Ontario, Canada were analyzed between January 1 2008
to September 30 2010. Patients were considered to have diabetes if at least one of
the following conditions was met: 1) physician diagnosed type 1 or 2 diabetes; 2)
1 measurement of HbA1 greater than the recommended target; or 3) at least one
prescription for a diabetes medication. RESULTS: A total of 76,077 adult patients
with representative data were included between 2008-2010. Prevalence of T2DM
was 7.9% and Type 1 diabetes was 2.9%. Patients on Lantus had less hypertension,
nephropathy or Stage 5 kidney disease than NPH or Premix insulin patients
(p0.05). Patients receiving Premix insulin tended to have more primary care visits,
ER visits, hospitalizations and total referrals than Lantus. More patients received
new scripts for NPH than Lantus or Premix insulin during the study period. The
average dose of Lantus was 10.5-10.7 units, with a high rate of annual renewal
(89.8-96.6%) for the same dose or any dose (93.8-98.7%). There were very few dose
switches or discontinuations for Lantus while NPH and Premix insulin were re-
newed less, underwent more dose switches and less discontinuations.
CONCLUSIONS: In a real-world setting the prevalence of diabetes was similar to
nationally reported data. Patients receiving Lantus tended to have less hyperten-
sion, nephropathy or Stage 5 kidney disease, while those who took Premix insulin
utilized more health services than Lantus or NPH. Lantus scripts were renewed
more often, had less dose changes or switches and less discontinuations than NPH
or Premix insulin.
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OBJECTIVES: A once-weekly formulation of exenatide (EQW) received positive
opinion from the EMA in April 2011 for the treatment of type 2 diabetes. No head-
to-head study of EQW and liraglutide 1.2mg once-daily (the dose recommended by
NICE) has been conducted therefore a network meta-analysis to compare EQW to
liraglutide 1.2mg in terms of effect on HbA1c was performed.METHODS:A system-
atic review was conducted to identify randomized controlled trials of EQW and
liraglutide (1.2mg and 1.8mg) of 24 weeks or more, and the common comparators
insulin glargine and exenatide bid to allow a network meta-analysis. Additionally,
the manufacturing companies were asked to provide any unpublished data from
studies meeting the criteria. 22 studies including 10,816 patients met our inclusion
criteria. Treatments were compared in terms of mean difference in HbA1c relative
to placebo. Additionally, EQW was compared to both doses of liraglutide, and lira-
glutide 1.2mg was compared to liraglutide 1.8mg. RESULTS: Results from random
effects models controlling for baseline HbA1c are presented. Analysis of change in
HbA1c produced estimated mean differences relative to placebo of -1.15% (95% CI
-1.31, -1.00) for EQW, -1.01% (95% CI -1.18, -0.85) for liraglutide 1.2mg, and -1.18%
(95% CI -1.32%, -1.04%) for liraglutide 1.8mg. The comparison of EQW to liraglutide
1.2mg and liraglutide 1.8mg showed a mean difference (95% CI) of -0.14% (-0.34,
0.06) and 0.03% (-0.14, 0.18) respectively. Liraglutide 1.2mg compared to liraglutide
1.8mg showed a mean difference in HbA1c of 0.17% (0.02, 0.30). Results were con-
sistent when controlling for use of background antihyperglyemic medications.
CONCLUSIONS: Our analysis suggests EQW and both doses of liraglutide have
robust and similar efficacy with respect to lowering of HbA1c. Further analysis is
warranted to investigate the inconsistency between the direct and indirect evi-
dence with respect to the comparison of EQW to liraglutide 1.8mg.
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OBJECTIVES: To evaluate weight change and glycemic control in patients age 65
with type 2 diabetes (T2DM) in a usual-care setting. METHODS: Treatment naïve
patients age 65 years with T2DM and a prescription (index date) for a sulfonylurea
(SU), metformin (MET), thiazolidinedione (TZD), GLP-1 agonist (GLP-1), or DPP-4
inhibitor (DPP-4) were identified in an electronic medical record database from
1/1/2000 to 6/30/2010. HbA1c 7% or 7% and weight gain or loss of 3% were
assessed 1 year post-index. Logistic regression identified the likelihood of weight
loss and attaining HbA1c goal by antidiabetic drug class, controlling for baseline
HbA1c and weight, and for weight change for HbA1c goal attainment. RESULTS: Of
12,473 patients, 46.4% were male and the mean age was 71.7 (3.9) years. At base-
line 26.7% had HbA1c7.0%; mean weight 86.8 (18.7) kg. Breakdown by drug class
was: SU - 31.0%, MET - 55.0%, TZD - 11.6%, DPP-4 - 1.9%, and GLP-1 - 0.6%. At 1 year,
34.8% lost3% of body weight and 46.5% had an HbA1c7.0%. In logistic regression
analyses, MET and DPP-4 (OR 1.4 and 1.36; p.05) were associated weight loss
relative to SU, TZDs were negatively associated with weight loss (OR 0.86; p.05),
and GLP-1 did not differ (OR 1.55; p0.08). Patients who lost weight were 2.26 times
as likely as those who did not to attain HbA1c goal (p.05). Drug class was not
associated with HbA1c goal attainment (p0.05). CONCLUSIONS: In patients with
T2DM age 65, those who lost weight were more likely to attain HbA1C goal than
those who did not. MET and DPP-4 were associated with weight loss vs. SU, but drug
class was not associated with HbA1C goal attainment. These findings support
guideline recommendations to consider weight-effect properties of antidiabetics
in treating T2DM with data specific to patients age 65.
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OBJECTIVES: This post hoc analysis analyzed the number of patients needed to be
treated (NNT) with the GLP-1 receptor agonist exenatide once weekly (ExQW) vs
titrated insulin glargine (IG) over 26 weeks to allow one additional patient to
achieve single or combined recommended treatment goals. METHODS: Data from
the DURATION-3 trial was analyzed retrospectively. Treatment targets included: 1)
glycaemia (HbA1c 6.5% or fasting plasma glucose (FPG) 7 mmol/L); 2) systolic
blood pressure (SBP130 mmHg); 3) low-density lipoprotein cholesterol (LDL2.59
mmol/L); and 4) weight loss or maintenance. Hypoglycemic events were also as-
sessed. NNT was calculated for the entire intent-to-treat (ITT) population (ExQW
n233, IG n223) and for subpopulations of patients on different background ther-
apies (metformin  sulfonylurea). NNT was calculated using 1/Absolute Risk Re-
duction (percent of patients reaching goal in the ExQW treatment arm - percent of
patients reaching goal in the IG treatment arm). RESULTS: Baseline mean charac-
teristics were similar for both treatment groups: 45-48% women, age 58 years,
HbA1c 8.3%, and body mass index 32 kg/m2. Regardless of background therapy, 8
patients would need to be treated with ExQW in place of IG for 26 weeks to allow
one additional patient to attain the HbA1C goal. Five patients (ITT) would need to be
treated with ExQW vs IG to allow one additional patient to attain the HbA1c goal
with weight control and the absence of hypoglycaemia. Furthermore, 14 patients
(ITT) would need to be treated with ExQW versus IG to allow one additional patient
to reach combined HbA1c, SBP, and LDL goals. Only the FPG goal favored insulin use
with an NNT of -8 (ITT). Minor differences in the NNT values were observed be-
tween subpopulations for most goals. CONCLUSIONS: Both ExQW and IG treated
patients achieved therapeutic target goals. In this post hoc analysis the NNT results
favored ExQW for most goals.
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LIRAGLUTIDE FOR TYPE 2 DIABETES IN CLINICAL PRACTICE: A RETROSPECTIVE
ANALYSIS OF THE GE CENTRICITY EMR DATA
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OBJECTIVES: Exenatide twice daily (exenatide) and liraglutide once daily, GLP-1
receptor agonists, have demonstrated improvements in glycemic outcomes for
patients with type 2 diabetes (T2D) in randomized clinical trials. We evaluated A1c
outcomes for patients initiating exenatide or liraglutide in a real-world setting.
METHODS: This retrospective cohort study used data from the Medical Quality
Improvement Consortium of ambulatory medical practices that use Centricity Of-
fice from GE Healthcare IT as their electronic medical record. Patients with T2D
receiving a prescription between Jun 2005 and May 2011 were identified (ex-
enatide61,485; liraglutide9,316). Baseline A1c measures were documented from
45 days prior to 15 days after initiating exenatide or liraglutide with follow-up
measures documented at 6 months45 days. An ANCOVA model including base-
line A1c, age, gender, concomitant glucose-lowering medications, and modified
Charlson Comorbidity Index (CCI) was used to estimate least squares mean A1c.
RESULTS: Mean(SD) age was 55(12) and 55(12), CCI 2.0(1.3) and 2.1(1.3), % male 41%
and 42% for exenatide and liraglutide patients, respectively. Baseline BMI was
38.4(7.8) and 37.9(7.7) for exenatide and liraglutude patients, respectively, who had
baseline and 6 month BMI data. Of patients not at A1c goal of7.0% at baseline, the
mean(SD) baseline A1c was 8.7(1.4) for exenatide and 8.6%(1.3) for liraglutide, and
at 6 months was 8.0%(1.6) for exenatide and 7.9%(1.6) for liraglutide; 29.8% of pa-
tients receiving exenatide and 30.8% of patients receiving liraglutide achieved7%
A1c goal at 6 months. At baseline, 47% of exenatide patients were prescribed 10
mcg BID daily; 7.7% and 83.9% of liraglutide patients were prescribed 1.2 and 1.8 mg
daily, respectively. At 6 months, 66% of exenatide patients were prescribed 10 mcg
BID daily; 11.2% and 75.4% were prescribed liraglutide 1.2 and 1.8 mg daily,
respectively. CONCLUSIONS: In this retrospective cohort study, glycemic out-
comes similarly improved for patients initiating exenatide or liraglutide.
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GLARGINE UTILISATION IN RUSSIA: A PROSPECTIVE STUDY TO EVALUATE
PATIENTS SWITCHED FROM NPH INSULIN TO INSULIN GLARGINE COMPARED
WITH THOSE MAINTAINED ON NPH
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OBJECTIVES: The LAntus Utilisation in RUSsia Study 2 (LAURUS 2) was an obser-
vational study undertaken at 245 sites as a follow-up to the LAURUS study. It
evaluated the efficacy of switching patients with type 2 diabetes mellitus (T2DM)
from NPH insulin to insulin glargine in real-life clinical practice.METHODS: Eligible
adult patients had taken NPH and 2 oral antidiabetes drugs (OADs) for 12 months.
During the 12-week study period all patients continued OADs. The active arm
included patients whose physicians switched their basal insulin from NPH to
glargine. Patients in the control group continued on NPH. Primary end point was
change in HbA1C. Secondary end points included changes in fasting blood glucose
(FBG) and insulin dose and hypoglycaemic episodes (HEs). RESULTS: Data were
available for 2395 of the 3000 enrolled patients. Patients had a mean duration of
diabetes of 9.3  5.1 y and mean duration of insulin therapy of 2.6  2.6 y. Mean
baseline HbA1c was 9.0  1.5 % and 9.2  1.4 % in the NPH and glargine groups,
respectively. After 12 weeks, mean HbA1c decreased by 0.6 % and 1.7 % in the NPH
and glargine groups, respectively (P 0.001). HbA1c  7% was attained by 8.4% and
25.8% of patients, respectively. Mean FBG decreased 1.4 1.7 mmol/L and 3.3 2.1
mmol/L, respectively (P 0.001). Mean insulin dose increased in both groups. At
baseline,  1 severe hypoglycaemic episode was reported by 0.4% and 0.7% of NPH
and glargine patients, respectively. At 12 weeks, no glargine patients reported se-
vere hypoglycaemia, but 2 (0.8%) NPH patients had at least 1 episode.
CONCLUSIONS: In this observational study, switching patients with T2DM who
were inadequately controlled on NPH to glargine improved glycaemic control with
minimal incidence of severe hypoglycaemia.
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A PROSPECTIVE REGISTRY TO IDENTIFY PATIENTS’ CHARACTERISTICS
ASSOCIATED WITH ACHIEVING TARGET METABOLIC CONTROL AFTER THREE
MONTHS TREATMENT WITH INSULIN GLULISINE IN TYPE 1 AND 2 DIABETES
MELLITUS PATIENTS PREVIOUSLY UNCONTROLLED ON BASAL INSULIN AND/
OR OTHER ANTI-DIABETIC TREATMENT (API REGISTRY)
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OBJECTIVES: Results from Canadian population-based studies show that glycae-
mic control (HbA1c 7.0%) is often not achieved in patients with either type 1
(T1DM) or type 2 (T2DM) diabetes mellitus. The aim of this prospective registry was
to identify patient characteristics associated with achieving HbA1c 7.0% in a
real-life setting 3 months after adding insulin glulisine to previous anti-hypergly-
caemic therapies. METHODS: The API registry included adult patients with T1DM
or T2DM who were receiving basal insulin ( anti-diabetic agents) and still had
HbA1C 7%. Patients for whom the treating physician had initiated the addition of
insulin glulisine within the month prior to study entry were assessed at baseline
and 3 months. Logistic regression using the backward elimination technique was
performed to identify the patient characteristics. RESULTS:HbA1C was available at
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